MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. NASDAQ 0.00%. Join Stocktwits for free stock discussions, prices, and market sentiment with millions of investors and traders. Get short term trading ideas from the MarketBeat Idea Engine. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Synergy Pharmaceuticals has a market capitalization of $0.00 and generates $16.82 million in revenue each year. In CIC, Phase 3 information were discharged in June 2015, and the outcomes were stellar, which moved the stock from $4.6 to $9. Stop-loss: $0.01 (-6.00%) * StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock … Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. To see all exchange delays and terms of use please see disclaimer. Some companies that are related to Synergy Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS). Get the latest %COMPANY_NAME% SGYP detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Home > Boards > US OTC > Delisted > Synergy Pharmaceuticals Inc. (fka SGYPQ) Add Price Alert Hide Sticky Hide Intro SYNERGY PHARMACEUTICALS INC: Add to my list. One way to short a stock is to buy put options. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Wall Street analysts have given Synergy Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. SGYP stock quote, chart and news. 0.0300 0.0000 (0.00%) At close: 8:42AM EST. Issues will remain on this list until the first business day after the issue is delisted. Synergy Pharmaceuticals Stock Forecast NASDAQ:SGYP Delisted. Company profile page for Synergy Pharmaceuticals LLC including stock price, company news, press releases, executives, board members, and contact information International Land Alliance (ILAL) Is A Stock That’s Hard To Ignore Sienna Biopharmaceuticals, Inc. (SNNA) Stock: A Biotech Stock That’s Falling Inovio Pharmaceuticals, Inc. (INO) Stock: Seeing Declines In … Symbol Last price; Stocks: Gainers. DOW 31,148.24. Qol/nautic may want to aquire sgyp or they may wanted to make a trade, my guess is they want to buy or partner. Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP.". 134.24k followers • 20 symbols Watchlist by Yahoo Finance. DOW 0.00%. Synergy Pharmaceuticals got the financing news long awaited and the stock is still trading at the lows. Report Split - Wrong Prices/Values Doesn't exist anymore Wrong Signals NASDAQ Stock Exchange > Drug Manufacturers - Other > Healthcare × Create a Watchlist. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. S&P 500 3,886.83 (+0.39%) MarketScreener Homepage > Equities > Nasdaq > Synergy Pharmaceuticals Inc . Based on aggregate information from My MarketBeat watchlists, some companies that other Synergy Pharmaceuticals investors own include Novavax (NVAX), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), Inovio Pharmaceuticals (INO), ACADIA Pharmaceuticals (ACAD), Cara Therapeutics (CARA), OPKO Health (OPK), Gilead Sciences (GILD), Exelixis (EXEL) and SELLAS Life Sciences Group (SLS). Vote “Outperform” if you believe SGYP will outperform the S&P 500 over the long term. NEW BOARD: To learn more about our 2021 Pandemic Protection Program and stay apprised of the progress we are making thanks to your collective support, click this link & then bookmark it. On March6, 2019, the Company received a written notice from Nasdaq that the Company’s common stock would be delisted from Nasdaq at the open of business on March8, 2019. Rooms Shows Rankings Earnings Calendar Shop. All rights reserved. Get the latest %COMPANY_NAME% SGYP detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Federal bankruptcy laws govern how companies go out of business or recover from crippling debt. factors . Synergy Pharmaceuticals Stock Forecast NASDAQ:SGYP Delisted. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant-... See More. This new listing could be the biggest bet of 2021. View SGYP's most recent analyst ratings, analyst estimates and price targets at MarketBeat. Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) issued its quarterly earnings data on Thursday, November, 8th. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Synergy Pharmaceuticals Inc. (SGYP) Add to watchlist. Oil prices head lower, eyeing their first session loss of the month. Synergy Pharmaceuticals Inc (SGYP) investors sentiment decreased to 0.33 in 2018 Q4. SGYP stock quote, chart and news. Compare key indexes, including Nasdaq Composite, Nasdaq-100, Dow Jones Industrial & more. The stock market is where one has to invest in a lot and wait for the results. 10:18a. Learn more. ©finra. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. Nabisco plant to close, leaving as many as 600 jobless. Sell now cut your losses it will drop to .01 or below but by April or May it will be near 50 cents. View SGYP's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings at MarketBeat. Get Synergy Pharmaceuticals LLC's stock price today. Synergy Pharmaceuticals (NASDAQ:SGYP) is a little top exploration stage biotech organization recorded on the Nasdaq. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. How Synergy Pharmaceuticals Stock Reacted To The News As we can expect any time positive news comes out about a biotech company, SGYP had a great day … S&P 500 0.00%. 2.2k Liked . Our Stock Picks. If you’ve got money invested in the market – and especially in popular tech stocks – this is critical information for the days ahead…, VP of Investor Relations and Corp. Communications, Start Your Risk-Free Trial Subscription Here, 3 Oil & Gas Stocks Worth Watching in 2021, U.S. Steel Stock is an Economic Recovery Buy Here, American Axle Manufacturing Stock is an Automotive Recovery and Electrification Play, 3 Health Care Stocks That Could Double by Year End, Toyota Doubles-Down On The EV Market, Again, iRobot Investors Clean Up After Q4 Results, Everi Holdings (NYSE: EVRI) Stock is an Under the Radar iGaming Play, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks, CORRECTING and REPLACING Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update, Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins, Identify IBS Treatment Market Regional Growth Drivers Electrifying Development Pace, FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC - UXIN, SGYP & MHLD, FRIDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm, DEADLINE FRIDAY REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm, DEADLINE FRIDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Synergy Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm, SGYP & MHLD - Class Action Bronstein, Gewirtz & Grossman, LLC, SYNERGY INVESTORS APRIL 12th DEADLINE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Synergy Pharmaceuticals Inc.; Encourages Investors With Losses In Excess of $100K to Contact the Firm – SGYP, SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – SGYP, Class Action Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD, Class Action Reminder Bronstein, Gewirtz & Grossman, LLC - SGYP & MHLD, Receive Analysts' Upgrades and Downgrades Daily. As previously announced, on December12, 2018, Synergy Pharmaceuticals Inc., a Delaware corporation (the “Company”) and its wholly-owned subsidiary, Synergy Advanced Pharmaceuticals,Inc., a … The Company’s securityholders are cautioned that trading in the Company’s securities during the pendency of the Chapter 11 Filings is highly speculative and poses substantial risks. Unusually active option classes on open May 23rd SGYP IP CRM BBY EWZ Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]. TipRanks Archive Biotech Roundup: Analysts Weigh In on Valeant Pharmaceuticals Intl Inc (VRX), Synergy View %COMPANY_NAME% SGYP investment & stock information. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. See what's happening in the market right now with MarketBeat's real-time news feed. SGYP stock's under-performance is due to Trulance sales not ramping up fast enough and that could change in the very near future. Get Synergy Pharmaceuticals LLC's stock price today. NASDAQ Updated May 1, 2019 8:00 PM The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. Following this news, Synergy's stock price fell $0.97 per share, or 69.3%, to close at $0.43 per share on October 26, 2018. Cancel. Current price $0.03 : 52-week high $2.23 : Prev. SGYP Dividend History & Description — Synergy Pharmaceuticals Inc. Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Trending now. Learn more. TECH UPDATE: If you have been experiencing slower than normal page loads for the past couple of weeks, click this link to learn more about a possible fix. SGYP Stock Quotes API . Synergy Pharmaceuticals' management team includes the following people: Tech Stocks to drop 92%?? Users completing forms for companies listing on The Nasdaq Stock Market will need to provide the company's Central Index Key (CIK) code or CUSIP along with the company's current or reserved trading symbol. Synergy Pharmaceuticals does not have a long track record of dividend growth. The ratio has worsened, as 23 funds increased or opened new stock … Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. At last check, SGYP stock was up 12.2% at $4.07, on track for its best day since late December. VAALCO Energy, Inc. (NYSE:EGY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain... Allegheny Technologies Incorporated (NYSE:ATI) Files An 8-K Results of Operations and Financial Condition, Newmont Mining Corporation (NYSE:NEM) Files An 8-K Submission of Matters to a Vote of Security Holders, ALIGN TECHNOLOGY, INC. (NASDAQ:ALGN) Files An 8-K Costs Associated with Exit or Disposal Activities, SIMMONS FIRST NATIONAL CORPORATION (NASDAQ:SFNC) Files An 8-K Financial Statements and Exhibits, Cannabis Distributor humble+fume to Build 48North’s Extraction Facility in Ontario, Isodiol Rolls Out Cannabis Vending Machine in Selected Powerhouse Gym Locations, Delphi Technologies PLC (NYSE:DLPH) gets upgraded to Buy by Bank of America, The Walt Disney Company (NYSE:DIS) has coverage initiated with a Overweight rating, California Resources Corp (NYSE:CRC) gets downgraded to Sell by Goldman Sachs Group, Cannabis Stock News Daily Roundup April 12, Market Morning: Alexa Spying, Boeing Sensor History, Macron Spoils Scallop Dinner. Learn about financial terms, types of investments, trading strategies and more.